|
Object |
K20 |
Telomerase |
Cytology |
Bacterial |
| |
RT - |
PCR |
IHC |
|
|
|
Infection |
| |
M ± SE
(AU) |
|
% > UL |
% Positive |
M ± SE
(AU) |
% > UL |
% Positive |
% Positive |
| Control |
14.3 ± 1.5 |
1/15
6.7 % |
0 % |
29.3 ± 5.9 |
2/15
13.3 % |
0/15
0 % |
1/15
6.7 % |
| Benign |
13.8 ± 0.8 |
4/20
20 % |
20 % |
61.8 ± 8.5* |
14/20
46.7 % |
0/20
0 % |
10/20
33.3 %* |
| Malignant |
27.5 ± 1.6*# |
40/45
89 % |
26/45
58 % |
117 ± 10.3*# |
39/45
87 % |
23/45
51 %*# |
33/45
73.3%*# |
| TCC |
27.8 ± 2.6*# |
25/30
83.3% |
13/30
43.3 % |
111.6 ± 14*# |
23/30
77 % |
16/30
53.3%*# |
21/30
70 %*# |
| SCC |
28.4 ± 3.1*# |
13/15
86.7 % |
6/15
40 % |
124.9 ± 16*# |
14/15
93.3% |
6/15
40 %*# |
12/15
80 %*# |
* Compared to control group, # Compared to benign group, Significant when p< 0.05
% > Upper limit = patient number more than 20 AU for K20 and 30AU for Telomerase. |